Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Spiridon Papapetropoulos MD_ PhD

VIEWS: 373 PAGES: 17

									                                                                                                1

            Spyridon (Spyros) Papapetropoulos MD, PhD
University of Miami, Miller School of               spapapetropoulos@med.miami.edu
Medicine
Associate Professor of Neurology                                  Tel: (+1)(305) 243-8461
Division of Movement Disorders                                    Fax: (+1)(305) 243-3321
Department of Neurology                                          Cell: (+1) (786) 201-8066
1501 NW 9th Avenue Room 2017
Miami, FL 33136

Work Experience:
   Associate Professor of Neurology, Department of Neurology, University of
                                                                                          2007-
    Miami, Leonard Miller School of Medicine
   Assistant Professor of Neurology, Department of Neurology, University of        2005 – 2007
    Miami, Leonard Miller School of Medicine
   Visiting Assistant Professor of Neurology, Department of Neurology,             2003 – 2004
    University of Miami, Leonard Miller School of Medicine
   Resident - Department of Neurology, Regional University Hospital of Patras,     2001 – 2003
    Greece
   Honorary Clinical Assistant, Movement Disorders Section - The National          2000 – 2001
    Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
   Resident in Internal Medicine - General County Hospital of Pyrgos, Greece       1999 – 2000
   Intern - Patras General Regional Hospital "Saint Andreas", Achaia, Greece       1998 – 1999




Professional Affiliations/ Titles:

   Director of Research, Division Of Movement Disorders, Department of Neurology, University
    of Miami, Miller School of Medicine.
   Director of the Patras Parkinson’s disease DNA Bank
   Leading Member of the Global Genetics Consortium for Parkinson’s disease (GEO-PD)
   Member of the scientific board and clinical consultant of the University of Miami Brain
    Endowment BankTM.
   Member of the American Academy of Neurology (AAN)
   Member of the Movement Disorders Society (MDS)
   Member of the Society for Neuroscience (SfN)
   Member of the Greek Neurological Society
   Board Certified in Neurology in the European Union (EU)



Education:
                                                                  S. Papapetropoulos MD, PhD
                                                                                                 2


Degree                             Institution
Medical Degree (MD)- top of the    University of Patras, School of Health Sciences,       1997
Class of ‘97                       Faculty of Medicine, Greece
Doctorate (PhD)- with Honors       University of Patras, School of Health Sciences,       2001
                                   Faculty of Medicine, Greece


Research/Business Skills:
 Neurogenomics/Translational Neurosciences
 Gene Expression Profiling/ Neurochemical Pathway Analysis/ Drug target
  identification
 Clinical descriptive studies/ Case ascertainment/ Clinical Database Management
 Clinical Trial organization/supervision
 Research Proposal/manuscript/research report preparation
 BioMedical Statistics
 Neuropathology
 Human resources management


Additional:
 Languages: Fluent in English, Greek and French
            Growing knowledge of Spanish, Italian
     Software: Selected research relevant list: Microsoft Word, Excell 2003/ Avadis, Strand
 Genomics Pvt LtD, Bangalore, India/ SPSS 11.0 Lead Tech Inc, Chicago, Illinois/ SigmaPlot, SPSS
 Inc/ Adobe Photoshop, BioExpressTM CNS Suite, Genelogic Inc/ Pathway Studio, Ariadne
 Genomics Inc Rockville, MD.


Peer-reviewed publications:
1. S Papapetropoulos, JR Jagid, A Guevara-Salcedo, C Singer, BV Gallo. Staged unilateral or
   bilateral STN-DBS? Mov Disord. 2007 in press.
2. M Eisa, S Papapetropoulos, Carlos Singer, B Jabbari. Treatment of painful legs, moving toes
   with botulinum toxin type A injections. European Neurology 2007-in press.
3. S Papapetropoulos, A Tzakis, C Sengun, C Reddy MD, K Boukas, J Zitser, C Singer. A case of
   pediatric acquired chronic hepatocerebral degeneration. Pediatric Neurology 2007-in press.
4. BK Scanlon, H Katzen, BE Levin, C Singer, S Papapetropoulos. A formula for the conversion of
   UPDRS-III scores to Hoehn and Yahr stage. Parkinsonism and related Disorders 2007-in
   press).
5. S Papapetropoulos, AA Argyriou. Painful Limbs Moving Extremities (PLME). Acta Neurol
   Scand. 2007 Oct 10; [Epub ahead of print]
6. S Papapetropoulos, J Jagid, C Sengun, C Singer, B Gallo. Objective monitoring of tremor and
   bradykinesia during deep brain stimulation of STN for Parkinson’s disease: A pilot study.
   (Neurology, 2007) (in press).


                                                                   S. Papapetropoulos MD, PhD
                                                                                                  3
7. S Papapetropoulos, N Adi, L Shehadeh, N Bishopric MD, C Singer, AA Argyriou, E Chroni. Is the
    G2019S LRRK2 mutation common in all southern European populations? (2007 Journal of
    Clinical Neuroscience) (in press).
8. S Papapetropoulos, AA Argyriou, G Mitsi, E Chroni. The G2019S LRRK2 mutation is
    uncommon amongst Greek patients with familial Parkinsons disease. Eur J Neurol. 2007
    Nov;14(11): e6
9. Papapetropoulos S, Ellul J, Argyriou AA, Chroni E. A prospective study of familial versus
    sporadic Parkinson's disease. Neurodegener Dis. 2007;4(6):424-7.
10. Papapetropoulos S, Argyriou AA, Polychronopoulos P, Chroni E. Frontotemporal and striatal
    SPECT abnormalities in a patient with Myoclonus-Dystonia Syndrome (MDS). (2007
    Neurodegenerative diseases) (in press).
11. S Papapetropoulos, S Baez, J Zitser, C Sengun, C Singer Retrocollis: classification, clinical
     phenotype, treatment outcomes and risk factors. Eur Neurol. 2007 Oct 4;59(1-2):71-75
12. S. Papapetropoulos, A Rapoport, R Guilad, A Eilam, Y Lampel, C Singer; M Sadeh. Moving
    fingers associated with Dupuytren's Disease. Eur Neurol. 2007 Oct 11;59(1-2):96-97
13. AG Papatsoris, S Papapetropoulos, C Singer, C Deliveliotis. Urinary and erectile dysfunction in
    Multiple System Atrophy (MSA). Neurourol Urodyn. 2007 Jun 11; [Epub ahead of print]
14. S Papapetropoulos, J Friedman, C Blackstone, GI Kleiner, C Singer. Progressive
    neurodegenerative syndrome in a patient with primary immunodeficiency. Mov Disord. 2007
    Aug 15;22(11):1664-6.
15. S Papapetropoulos, D McCorquodale. Optimizing human postmortem brain tissue gene
    expression profiling in Parkinson’s disease: From target “fishing” to translational
    breakthroughs. J Neurosci Res. 2007 May 14; [Epub ahead of print]
16. SJ Lincoln, OA. Ross, NM. Milkovic, DW. Dickson, A Rajput, CA. Robinson, ML. Rajput, S
    Papapetropoulos, DC. Mash & MJ. Farrer. Quantitative PCR based screening of α-Synuclein
    multiplication in multiple system atrophy. Parkinsonism Relat Disord. 2007 Feb 7; [Epub
    ahead of print]
17. S. Papapetropoulos. Is there a role for naturally-occurring cyanobacterial toxins in
    neurodegeneration? The β-MAA paradigm. Neurochem Int. 2007 Jan 14; [Epub ahead of
    print]
18. TG Lesnick, S Papapetropoulos, DC Mash, J Ffrench-Mullen, M de Andrade, JR. Henley, WA
    Rocca, JE Ahlskog, DM Maraganore. A Genomic Pathway Approach to a Complex Disease:
    Axon Guidance and Parkinson's disease. PLoS Genet. 2007 Jun 15;3(6):e98
19. S Papapetropoulos, N Adi, L Shehadeh, DC Mash, N Bishopric. Expression Of α-Synuclein
    mRNA in Parkinson’s disease. Mov Disord. 2007 May 15;22(7):1057-9.
20. S Papapetropoulos, MJ Farrer, JT Stone, NM Milkovic, OA Ross, L Calvo, D McQuorquodale &
    Deborah C. Mash. Phenotypic associations of tau and ApoE in Parkinson’s disease. Neurosci
    Lett. 2007 Mar 6;414(2):141-4
21. S Papapetropoulos, C Singer. Eating dysfunction associated with oromandibular dystonia:
    Clinical characteristics and treatment considerations. Head Face Med. 2006 Dec 7;2:47.
22. S Papapetropoulos, D McCorquodale. Gene Expression Profiling in Parkinson’s disease:
    Discovery of valid biomarkers, molecular targets and biochemical pathways. Future Neurol
    (2007) 2(1) 29-38.
23. S Papapetropoulos, C Singer. Botulinum toxin in Movement Disorders. Semin Neurol. 2007
    Apr;27(2):183-94.
24. Papapetropoulos S, Tuchman A, Laufer D, Papatsoris AG, Papapetropoulos N, Mash DC.
    Causes of death in Multiple System Atrophy. J Neurol Neurosurg Psychiatry. 2007
    Mar;78(3):327-9
                                                                     S. Papapetropoulos MD, PhD
                                                                                                  4
25. Papapetropoulos S, Papapetropoulos N, Singer C. Primary cranio-cervical dystonia presenting
    as a respiratory emergency. Neurology. 2007 Jan 30;68(5):388-9.
26. S Papapetropoulos, DC Mash. Motor fluctuations and dyskinesias in advanced/end stage
    Parkinson’s disease: a study from a population of brain donors. J Neural Transm. 2007
    Mar;114(3):341-5
27. LI Golbe, G Di Iorio, K Markopoulou, A Athanassiadou, S Papapetropoulos, RL.Watts, JM.
    Vance, V Bonifati, TA. Williams, JR Spychala, S Stenroos, WG Johnson. Glutathione S-
    transferase polymorphisms and onset age in α-synuclein A53T mutant Parkinson’s disease.
    American Journal of Medical Genetics 2006 2006 Oct 10; [10.1002/ajmg.b.30450]
28. S Papapetropoulos, J ffrench-Mullen, D McCorquodale, Y Qin, J Pablo, DC Mash. Multiregional
    gene expression profiling identifies MRPS6 as a candidate gene for Parkinson’s disease. Gene
    Expr. 2006;13(3):205-15.
29. S Papapetropoulos, A Tuchman, D Laufer, DC Mash. Hallucinations in Multiple System
    Atrophy. Parkinsonism Relat Disord. 2007 Apr;13(3):193-4.
30. S Papapetropoulos, DS Lundy, RR Casiano, C Singer. Laryngeal dystonia as a presenting
    symptom of young-onset Parkinson’s disease. Movement Disorders (10.1002/mds.21184)
31. C Singer, S Papapetropoulos, G Uzcategui, L Vela. Efficacy and tolerability of Amantadine: A
    retrospective review of old and new indications. Journal of Applied Research 6 (3) 2006 240-
    245.
32. C Singer, S Papapetropoulos, Ram Ayyar, Ashok Verma. Botulinum toxin type A therapy in a
    patient with cervical dystonia and amyotrophic lateral sclerosis. Movement Disorders (in
    press 2007)
33. S Papapetropoulos, C Singer. Sporadic Geniospasm: Report of a case. Mov Disord. 2007 Feb
    15;22(3):434
34. S Papapetropoulos, C Singer. Bilateral mirror writing movements (mirror dystonia) in a
    patient with writer's cramp: Functional correlates. Mov Disord. 2007 Jan;22(1):149
35. DM Maraganore, M de Andrade, A Elbaz, MJ Farrer, JP Ioannidis, R Krüger, WA Rocca, NK.
    Schneider, TG. Lesnick, SJ Lincoln, MM Hulihan, JO Aasly, T Ashizawa, MC Chartier-Harlin, H
    Checkoway, C Ferrarese, G Hadjigeorgiou, N Hattori, H Kawakami, JC Lambert, T Lynch, GD
    Mellick, S Papapetropoulos, A Parsian, A Quattrone, O Riess, EK Tan, C Van Broeckhoven.
    Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.
    JAMA. 2006 Aug 9;296(6):661-70.
36. S Papapetropoulos, C Singer. Treatment of Primary Writing Tremor (PWT) with botulinum
    toxin type A injections: Report of a case series. Clin Neuropharmacol. 2006 Nov-
    Dec;29(6):364-7.
37. S Papapetropoulos, DC Mash. Insular pathology in Parkinson's disease patients with
    orthostatic hypotension. Parkinsonism Relat Disord. 2007 Jul;13(5):308-11.
38. S Papapetropoulos, M Basile, DC Mash. Dopaminergic innervation of the human striatum in
    Parkinson’s disease. Mov Disord. 2007 Feb;22(2):286-8
39. S Papapetropoulos, C Singer. Cervical dystonia as a presenting symptom of Parkinson's
    disease. Parkinsonism Relat Disord. 2006 Dec;12(8):514-6..
40. S Papapetropoulos, C Singer. A case of painless arms/moving fingers responsive to botulinum
    toxin A injections. Parkinsonism and Related Disorders 2007 Feb;13(1):55-6.
41. S Papapetropoulos, JM Villar, DC Mash. Is ischemic cerebrovascular disease a risk factor for
    dementia in patients with Parkinson’s disease?” Acta Neurol Scand. 2006 May;113(5):353-4.
42. S Papapetropoulos, C Singer, O. Ross, M. Toft, MJ. Farrer, D.C. Mash. Clinical heterogeneity of
    Lrrk2 G2019S. Arch Neurol. 2006 Sep;63(9):1242-6.


                                                                     S. Papapetropoulos MD, PhD
                                                                                                  5
43. PA Cox, SA Banack; S Murch; A Bell; P Nunn; W Bradley; D Mash; S Papapetropoulos; et al.
    Lack of β-methylamino-L-alanine in brain from controls, AD, or Chamorros with PDC.
    Neurology 2005 (e-letter).
44. AA Argyriou, E Chroni, A Koutras, G Iconomou, S Papapetropoulos, P Polychronopoulos, MD1;
    HP. Kalofonos. Paclitaxel-induced peripheral neuropathy: Could really vitamin E
    supplementation prevent it? J Pain Symptom Manage. 2006 Sep;32(3):237-44.
45. P. Polychronopoulos, AA Argyriou; S. Papapetropoulos, P. Gourzis, G. Rigas, E. Chroni.
    Wilson’s disease and Benign Partial Epilepsy with Centrotemporal (or Rolandic) Spikes:
    report of a case. 2005 Epilepsy and Behavior; 2006 Mar;8(2):438-41.
46. S. Papapetropoulos. Drug-Induced Psychosis in Parkinson Disease: Phenomenology and
    Correlations among psychosis rating instruments. Clinical Neuropharmacology 2006 Jan-
    Feb;29(1):59.
47. S. Papapetropoulos, J. Gonzalez, L. Jean-Gilles, D.C. Mash. Cortical and amygdalar Lewy body
    burden in Parkinson’s disease patients with malignant visual hallucinations. Parkinsonism
    Relat Disord. 2006 May;12(4):253-6.
48. A.G. Papatsoris, Ch. Deliveliotis, C. Singer, S. Papapetropoulos. Erectile dysfunction in
    Parkinson’s disease. Journal of Urology 2006 2006 Mar;67(3):447-51
49. S. Papapetropoulos, D.C. Mash. Visual Hallucinations in Progressive Supranuclear Palsy
    (PSP). European Neurology 2005;54(4):217-9.
50. S Papapetropoulos, C Singer. Painless legs moving toes in a patient with Wilson’s disease.
    Mov Disord. 2006 Apr;21(4):579-80.
51. O. Ross, M. Toft, J.L. Johnson, D.C. Mash, S Papapetropoulos, I. Litvan, M.F. Gordon, MJ. Farrer
    & DW. Dickson. Lrrk2 and Lewy body disease. Annals of Neurology 2006 Feb;59(2):388-93.
52. Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P,
    Kalofonos HP. Preventing Paclitaxel-Induced Peripheral Neuropathy: A Phase II Trial of
    Vitamin E Supplementation. J Pain Symptom Manage. 2006 Sep;32(3):237-44.
53. AA Argyriou, E Chroni, A Koutras, G Iconomou, S Papapetropoulos, P Polychronopoulos, H
    Kalofonos A randomized controlled trial evaluating the efficacy and safety of vitamin E
    supplementation for protection against cisplatin-induced peripheral neuropathy: final
    results.. Support Care Cancer. 2006 Nov;14(11):1134-40.
54. S Papapetropoulos, C Singer. Improvement of cervico-trunco-brachial segmental dystonia
    with topiramate. J Neurol. 2006 Apr;253(4):535-6.
55. S Papapetropoulos, C Singer. Primary Focal Lingual Dystonia. Mov Disord. 2006
    Mar;21(3):429-30.
56. S. Papapetropoulos, A.A. Argyriou, E. Chroni. No correlation between the clinical severity of
    autonomic symptoms (SCOPA-AUT) and electrophysiological test abnormalities in advanced
    Parkinson’s disease. Mov Disord. 2006 Mar;21(3):430-1.
57. S Papapetropoulos, JM Villar, J Gonzalez, DC Mash. Disparities in death certificates of
    Parkinson’s disease patients: a report from a population of brain donors. Mov Disord. 2006
    Oct;21(10):1791-2
58. Argyriou AA, Chroni E, Polychronopoulos P, Argyriou K, Papapetropoulos S, Corcondilas M,
    Lepoura N, Heras P. Headache characteristics and brain metastasis prediction in cancer
    patients. Eur J Cancer Care (Engl). 2006 Mar;15(1):90-5.
59. Argyriou AA, Koutras A, Polychronopoulos P, Papapetropoulos S, Iconomou G, Katsoulas G,
    Makatsoris T, Kalofonos HP, Chroni E. The impact of paclitaxel or cisplatin-based
    chemotherapy on sympathetic skin response: a prospective study. Eur J Neurol. 2005
    Nov;12(11):858-61.


                                                                     S. Papapetropoulos MD, PhD
                                                                                                   6
60. Papapetropoulos S, Ellul J, Argiriou AA, Chroni E, Lekka N. Effects of depression on the clinical
    phenotype of Parkinson's disease: A registry-based, case-control study. Clin Neurol
    Neurosurg. 2006 Jul;108(5):465-9.
61. S Papapetropoulos, C Singer. Lower Limb Post-Immobilization Dystonia in Parkinson’s
    disease. Journal of Neurological Sciences. 2005 Dec 15;239(1):111-4.
62. S Papapetropoulos, C Singer. A comparison of jaw-closure and jaw-opening idiopathic
    oromandibular dystonia. Parkinsonism and Related Disorders 2006 Mar;12(2):115-8.
63. S Papapetropoulos, C Singer. Adult-Onset Isolated Primary Focal Foot Dystonia. 2005
    Parkinsonism and Related Disorders. 2006 Jan;12(1):57-60.
64. S Papapetropoulos, C Singer. Lower Facial and neck dystonia after a cosmetic surgical
    procedure: report of a case. Movement Disorders 2006 Jan;21(1):125-126.
65. Gourzis P, Polychronopoulos P, Papapetropoulos S, Asimakopoulos K, Beratis S. Quetiapine in
    the treatment of focal tardive dystonia induced by other atypical antipsychotics. Clin
    Neuropharmacol 2005;28(4):195-196.
66. S Papapetropoulos, Carlos Singer, D McCorquodale J Gonzalez, DC Mash. Cause, Seasonality of
    Death and Co-Morbidities in Progressive Supranuclear Palsy (PSP). 2005 Parkinsonism and
    Related Disorders. 2005 Nov;11(7):459-63.
67. C Singer, S Papapetropoulos, L Vela. Use of Mirror Dystonia as Guidance for Injection of
    Botulinum Toxin in Writing Dysfunction. J Neurol Neurosurg Psychiatry 2005
    Nov;76(11):1608-9.
68. S Papapetropoulos, C Singer. Tardive Dystonia Associated with Ziprasidone. Am J Psy 2005
    Nov;162(11):2191
69. S Papapetropoulos. Regional alpha-synuclein aggregation, dopaminergic dysregulation and
    the development of psychotic symptoms in Parkinson’s disease. Journal of Neuropsychiatry
    and Clinical Neurosciences 2006;Spring 18(2):149-57.
70. S Papapetropoulos, J Gonzalez, DC Mash. Natural history of Progressive Supranuclear Palsy
    (PSP). A clinico-pathologic study from a population of brain donors. Eur Neurol
    2005;54(1):1-9.
71. C Singer, S Papapetropoulos, O Farronay. Childhood-onset Hemifacial Spasm: Successful
    treatment with Botulinum Toxin and Review of the Literature. Pediatric Neurology 2004;
    2005 Sep;33(3):220-2.
72. C Singer, D Lorenzo, S Papapetropoulos, A Mesa, B Bowen. Extrapontine myelinolysis
    associated with an eating disorder. Neurology 2005;64(12):2156-7.
73. C Singer, S Papapetropoulos, NI Spielholz. Primary Writing Tremor: Successful treatment
    with botulinum toxin injections. Clinical, pathophysiological and therapeutic observations.
    Movement Disorders 2005 Oct;20(10):1387-8.
74. S Papapetropoulos, C Singer. Primary writing tremor and writer’s cramp are different
    nosologic entities J Neurol Neurosurg Psychiatry 2005; (e-letter)
75. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease: from description to
    etiology. J Neurol. 252(7): p. 753-64.
76. Papapetropoulos S, Singer C. Management of the Extrapyramidal Syndrome in Chronic
    Acquired Hepatocerebral Degeneration (CAHD). Mov Disord 2005;20(8):1088-1089.
77. Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual
    hallucinations in Parkinson’s disease. J Neurol 2005 Oct;252(10):1223-8
78. S. Papapetropoulos, DC Mash. Alpha-synuclein aggregation and its relation to
    neurodegenerative diseases. Ann Neurol. 57(4): 605



                                                                      S. Papapetropoulos MD, PhD
                                                                                                  7
79. S. Papapetropoulos, A. Lieberman, J. Gonzalez, D.C. Mash. Can Alzheimer’s type pathology
    influence the clinical phenotype of Parkinson’s disease? Acta Neurol Scand 2005;111(6):353-
    9.
80. S Papapetropoulos, R Lopez-Alberola, L Baumbach, A Russell, MA Gonzalez, C Singer. A case of
    maternally transmitted juvenile Huntington’s disease with a very large trinucleotide repeat.
    Movement Disorders 2005; Oct;20(10):1380-3.
81. Terzi A, Papapetropoulos S, Kouvelas ED. Past Tense Formation and Comprehension of
    Passive Sentences in Parkinson’s disease: Evidence from Greek. Brain and Language 2005;
    Sep;94(3):297-303.
82. Papapetropoulos S, Singer C. Psychiatric comorbidity in a population of Parkinson's disease
    patients. Eur J Neurol. 2006 Aug;13(8):e1.
83. S. Papapetropoulos, C. Singer, J.M. Villar, J. Gonzalez, D.C. Mash. Does cigarette smoking
    provide clinically significant neuroprotection among patients diagnosed with Parkinson’s
    disease? Mov Disord. 20(5):641-2.
84. S. Papapetropoulos, D.C Mash. The neurochemical mechanism of rebound psychosis in
    Parkinson’s disease. Mov Disord. 20(4):515.
85. Heras P, Argyriou AA, Papapetropoulos S, Karagiannis S, Argyriou K, Mitsibounas D. The
    impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality
    of life of anaemic cancer patients. Eur J Cancer Care (Engl) 2005;14(2):108-12.
86. Argyriou AA, Polychronopoulos P, Ellul J, Papapetropoulos S, Andriopoulos I, Katsoulas G, et
    al. Clinical and epidemiological features of motor neuron disease in southwestern Greece.
    Acta Neurol Scand. 111(2):108-13.
87. C Singer, S Papapetropoulos, MA Gonzalez, A Lieberman. Rimantadine in Parkinson’s disease
    patients experiencing peripheral adverse effects from Amantadine: Report of a case series.
    Mov Disord. 20(7): p. 873-877.
88. Papapetropoulos S, Scaravilli T, Morris H, An SF, Henderson DC, Quinn NP, et al. Young onset
    limb spasticity with PSP-like brain and spinal cord NFT-tau pathology. Neurology
    2005;64(4):731-3.
89. Papapetropoulos S, Lieberman A, Gonzalez J, Singer C, Laufer D, Mash DC. Family history of
    dementia: dementia with lewy bodies and dementia in Parkinson's disease. J.
    Neuropsychiatry and Clinical Neurosciences 2006 Winter;18(1):113-6.
90. Papapetropoulos S, Gonzalez J, Mash DC. The effect of ischemic cerebrovascular disease on
    the survival duration and clinical characteristics of Parkinson's disease. A post-mortem study.
    Eur J Neurol; 2006 Jan;13(1):96-7
91. E Chroni, S Papapetropoulos, AA. Argyriou, T Papapetropoulos. A case of fatal progressive
    neuropathy. Delayed consequence of multiple bite s of a non-venomous snake. Clinical
    Neurology and Neurosurgery 2005 Dec;108(1):45-7.
92. Papapetropoulos S, Gonzalez J, Lieberman A, Mash DC. Dementia in Parkinson disease.
    Prevalence and clinical correlates from a population of brain donors. Int J Geriatr Psychiatry.
    20(5):418-22.
93. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al. Vitamin E for
    prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
    Neurology 2005;64(1):26-31.
94. Papapetropoulos S, Argiriou AA. Administration of selegiline is not associated with visual
    hallucinations in advanced Parkinson's disease patients. Parkinsonism Relat Disord.
    11(4):265-6.



                                                                     S. Papapetropoulos MD, PhD
                                                                                                  8
95. Papapetropoulos S, Argyriou AA, Liossis SN, Daousis D, Katsoulas G, Apostolopoulos D, et al. A
    case of L-dopa-responsive parkinsonian syndrome after low-dose oral methotrexate intake.
    Clin Neuropharmacol 2004;27(2):95-98.
96. Papapetropoulos S, Ellul J, Polychronopoulos P, Chroni E. A registry-based, case–control
    investigation of Parkinson’s disease with and without cognitive impairment. Eur J Neurol
    2004;11:347–351.
97. Papapetropoulos S, Argyriou AA, Ellul J, Chroni E. Comparison of motor fluctuations and L-
    dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease. Eur J
    Neurol 2004;11(2):115-119.
98. Papapetropoulos S, Ellul J, Argyriou AA, Talelli P, Chroni E, Papapetropoulos T. The effect of
    vascular disease on late onset Parkinson's disease. Eur J Neurol 2004;11(4):231-235.
99. Maraganore DM, Lesnick TG, Elbaz A, Chartier-Harlin MC, Gasser T, Kruger R, et al. UCHL1 is a
    Parkinson's disease susceptibility gene. Ann Neurol 2004;55(4):512-521.
100. Georgopoulos NA, Papapetropoulos S, Chroni E, et al. (2004) Spinocerebellar ataxia and
    hypergonadotropic hypogonadism associated with familial sensorineural hearing loss.
    Gynecol Endocrinol (19): 105-110
101. Chroni E, Papapetropoulos S, Gioldasis G, Ellul J, Diamadopoulos N, Papapetropoulos T.
    Guillain-Barre syndrome in Greece: seasonality and other clinico-epidemiological features.
    Eur J Neurol 2004;11(6):383-388.
102. Argyriou AA, Papapetropoulos S, Polychronopoulos P, Corcondilas M, Argyriou K, Heras P.
    Psychosocial effects and evaluation of the health-related quality of life in patients suffering
    from well-controlled epilepsy. J Neurol 2004;251(3):310-313.
103. Papapetropoulos S, Ellul J, Paschalis C, Athanassiadou A, Papadimitriou A,
    Papapetropoulos T. Clinical characteristics of the alpha-synuclein mutation (G209A)-
    associated Parkinson's disease in comparison with other forms of familial Parkinson's
    disease in Greece. Eur J Neurol 2003;10(3):281-286.
104. Papapetropoulos S, Argiriou AA, Ellul J. Clinical characteristics of late-onset Parkinson
    disease. Arch Neurol 2003;60(12):1815-1816;
105. Chroni E, Thomopoulos C, Papapetropoulos S, Paschalis C, Karatza CL. A case of relapsing
    Guillain-Barre syndrome associated with exacerbation of chronic hepatitis B virus hepatitis. J
    Neurovirol 2003;9(3):408-410.
106. Papapetropoulos S, Paschalis C, Athanassiadou A, Ellul J, Papapetropoulos T. No male
    predominance in alpha-synuclein PD but the affected female fetus might be less viable,
    Authors reply. J Neurol Neurosurg Psychiatry 2002;72:274-280.
107.    Papapetropoulos S, Paschalis C, Ellul J, Papapetropoulos T, Athanassiadou A. Survival
    duration of Parkinson's disease patients living in Greece who carry the G209A alpha-
    synuclein mutation. Mov Disord 2002;17(4):847-848.
108. Papapetropoulos S, Paschalis C, Athanassiadou A, Papadimitriou A, Ellul J,
    Polymeropoulos MH, et al. Clinical phenotype in patients with alpha-synuclein Parkinson's
    disease living in Greece in comparison with patients with sporadic Parkinson's disease. J
    Neurol Neurosurg Psychiatry 2001;70(5):662-665.



Submitted (under review) peer-reviewed publications:



                                                                     S. Papapetropoulos MD, PhD
                                                                                                     9
1. Pablo JP, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Basile M, Bradley WG, and Mash
   DC. Neurotoxic Non-Natural,Amino Acid BMAA is present in Brains of United States Patients
   with Sporadic ALS and Alzheimer's disease. (PNAS 2007)
2. R Lopez-Alberola, D Lorenzo, MA Gonzalez, C Sengun, C Singer, S Papapetropoulos,,
   Encephalitis lethargica: a reawakening from the past. (Neurology 2007)
3. D A Nation, H L Katzen, R A Rodriguez, J A Ledon, A Capano, S Papapetropoulos, BV Gallo, J R
   Jagid and B E Levin. Defining Sub-Threshold Depression in Parkinson s Disease. (JNNP 2007)
4. S Delgado, S Baez, C Singer, C Sengun, WA Sheremata, S Papapetropoulos. Progressive
   Multiple Sclerosis with Parkinsonism, dystonia and anti-Basal Ganglia antibodies (Movement
   Disorders 2007).
5. Papapetropoulos S, Glynos K, Zhou Z, Argyriou AA, Orfanos SE, Papapetropoulos A. No
   association of the insertion/deletion polymorphism of the Angiotensin Converting Enzyme
   (ACE) and Parkinson's disease. (Psychiatry and Clinical Neuroscienecs 2007).
6. Argyriou AA, Papapetropoulos S, Polychronopoulos P, Chroni E. Co-occurence of
   menengiomas and demyelization of the central nervous system: Coincidence or interrelation?
   (Neurological Research 2005).
7. AA Argyriou, M Koltzenburg, P Polychronopoulos, HP Kalofonos, Spiridon Papapetropoulos,
   Elizabeth Chroni. Peripheral nerve damage associated with administration of taxanes in
   patients with cancer.
8. N Adi, L Shehadeh, AV Ramachandran, DC Mash, N Bishopric, S Papapetropoulos. Gene
   expression of MT1 & MT2 receptors in Parkinson’s disease human post mortem brain.
   (Journal of Pineal Research 2007)
9. S Papapetropoulos, AA Argyriou, J Ellul, A Guevara Salcedo, E Chroni. Transient Global
   Amnesia and Total Serum Cholesterol Levels. (Eur J Neurol 2007)


Abstracts & Conference proceedings:
1. Papapetropoulos S, Athanassiadou A, Papadimitriou A, Ellul J, Polymeropoulos MH, Paschalis
   C. Specific clinical phenotype associated with alpha-synuclein Parkinson's disease in
   comparison to familial Parkinson's disease. J Neurol. 2000;247(Suppl. 3):III/35
2. Papapetropoulos S, Athanassiadou A, Papadimitriou A, Ellul J, Polymeropoulos MH, Paschalis
   C. Specific clinical phenotype associated with alpha-synuclein Parkinson's disease in
   comparison to sporadic Parkinson's disease. Mov Disord. 2000;15(Suppl.3):191-192.
3. Papapetropoulos S, Athanassiadou A, Papadimitriou A, Ellul J, Polymeropoulos MH, Paschalis
   C. Comparison of the clinical severity between α-Synuclein Parkinson's Disease and Familial
   Parkinson's Disease Patients. Park Rel Dis. 2001;7:S119
4. Papapetropoulos S, Ellul J, Talelli P, Katsoulas G, Chroni E. , Paschalis Ch. Cholesterol levels in
   patients with Transient Global Amnesia. Eur. J. Neur. 2002;(3) Supp2:114
5. Polychronopoulos P., Papapetropoulos S., Economou A., Paschalis C. Wilson’s disease and
   Benign Partial Epilepsy with Centrotemporal (or Rolandic) Spikes: report of a case. Epilepsia
   (2002) 43 suppl. 8, p654.
6. Papapetropoulos S, Ellul J, , Athanassiadou A, Paschalis C. Survival duration of parkinsonian
   patients carrying the G209A alpha-synuclein mutation living in Greece. Mov Disord (2002)17
   (supp5):S38.
7. Papapetropoulos S, Argyriou A. A., Neilas I, Ellul J, Polychronopoulos P, Demographic features
   and clinical characteristics of viral encephalitis in soouthwest Greece: A 12 year experience.
   Journal of Neurology (2003) suppl 2, p747.

                                                                       S. Papapetropoulos MD, PhD
                                                                                                      10
8. Talelli P, Chrisanthopoulou A, Terzis G, Gioldasis G, Papapetropoulos S, Argyriou A. A, Ellul J.
    Predicting severe strokes using common carotid artery intima media thickness in association
    with other risk factors. Journal of Neurology (2003) suppl 2, p703
9. A. Georgopoulos, S Papapetropoulos, E Chroni, ES Papadeas, PA Dimopoulos, V
    Kyriazopoulou, G Kourounis and VA. Tzingounis . Cerebellar ataxia and hypergonadotropic
    hypogonadism associated with familial sensorineural hearing loss. Journal of Neurology
    (2003) suppl 2, p521
10. Moutopoulou M, Argyriou AA, Katsoulas G, Papapetropoulos S, Chroni E. The effect of carpal
    tunnel syndrome in sympathetic skin responses recorded from the palm. Journal of
    Neurology (2003) suppl 2, p359
11. Polychronopoulos P, Economou A, Neilas I, Argyriou AA, Katsoulas G, Papapetropoulos S,
    Papapetropoulos Th. Alcohol-relatted seizures: a prospective study in a hospitalized cohort
    of adult patients. Journal of Neurology (2003) suppl 2, p371.
12. Papapetropoulos S, Ellul J, Argyriou AΑ, Chroni E. Positive family History has no effect on the
    clinical phenotype of Parkinson’s disease. 14th Conference of Southeast European Society for
    Neurology and Psychiatry (2003), Free Communication. Page 34.
13. P Heras, AA Argyriou, S Papapetropoulos, M Corcondilas, K Argyriou, P Polychronopoulos.
    Psychosocial effects and evaluation of the health-related quality of life in patients suffering
    from mild epilepsy. Epilepsia (2003) Vol.44 Sup. 8, p499
14. P Polychronopoulos, P Papathanasopoulos,               AA Argiriou, M Giannakopoulou, S
    Papapetropoulos, T Papapetropoulos. Sensorineural hearing loss: A reversible effect of
    Vigabatrin. Epilepsia (2003) Vol.44 Sup. 8, p467
15. S Papapetropoulos, J Ellul, E Chroni1, NP Lekka. The impact of depression and antidepressant
    treatment on motor function of patients with idiopathic Parkinson’s disease. Annals of
    General Hospital Psychiatry 2003, 2(Suppl 1):S105
16. S. Papapetropoulos, J. Ellul, P. Polychronopoulos, E. Chroni, T. Papapetropoulos. A registry-
    based, case control investigation of Parkinson's disease with and without cognitive
    impairment. Mov Disord (2004)19 (supp9):[P695]
17. S. Papapetropoulos, J. Gonzalez, A. Lieberman, D.C. Mash. Dementia in Parkinson disease.
    Prevalence and clinical correlates in a nationwide population of brain donors. Mov Disord
    (2004)19 (supp9);[P539]
18. S. Papapetropoulos, J. Gonzalez, A. Lieberman, D.C. Mash. Alzheimer disease (AD) pathology
    in patients clinically and pathologically diagnosed with Parkinson disease (PD). Are the
    symptoms different?. Mov Disord (2004)19 (supp9);[P619]
19. S. Papapetropoulos, J. Gonzalez, A. Lieberman, D.C. Mash. A comparison of demented patients
    with pathologically confirmed Parkinson disease (PD) and Alzheimer disease (AD) pathology
    and non-demented patients also with confirmed Parkinson disease and Alzheimer disease.
    Mov Disord (2004)19 (supp9);[P693]
20. C. Singer, S. Papapetropoulos, M.A. Gonzalez, A. Lieberman, E. Roberts Rimantadine as an
    alternative to amantadine in Parkinson patients with severe leg edema secondary to
    amantadine: Case reports. Mov Disord (2004)19 (supp9);[P694]
21. T. Scaravilli, S. Papapetropoulos, H. Morris, N.P. Quinn, F. Scaravilli, K.P. Bhatia. A patient with
    PSP-like brain and spinal cord NFT-tau pathology presenting as young onset spastic
    paraplegia. Mov Disord (2004)19 (supp9);[P1006]
22. L.I. Golbe, G. Di Iorio, K.M. Markopoulou, A. Athanassiadou, S. Papapetropoulos, R.L. Watts.
    Glutathione S-transferase P1 and Z1 alleles influence onset age in Parkinson's disease caused
    by the α-synuclein A53T mutation. Mov Disord (2004)19 (supp9);[P1072]


                                                                         S. Papapetropoulos MD, PhD
                                                                                                   11
23. S. Papapetropoulos, A. Argyriou, P. Polychronopoulos, P. Gourzis, T. Spiridonidis, S. Salakou,
    V. Sirrou, P. Papathanasopoulos: Myoclonus-dystonia syndrome associated with psychiatric
    disorders and findings in the brain perfusion SPECT. Journal of Neurology 2004; 251 (suppl
    III): 66
24. S. Papapetropoulos, A. Argyriou, S. Liossis, D. Daousis, G. Katsoulas, D. Apostolopoulos, E.
    Chroni: Parkinsonian syndrome as a side effect of oral methotrexate intake: case report.
    Journal of Neurology 2004; 251 (suppl III):67
25. A. Argyriou, P. Polychronopoulos, I. Andriopoulos, S. Papapetropoulos, G. Katsoulas, J. Ellul, S.
    Salakou, E. Chroni: Epidemiological features of motor neuron disease in southwestern
    Greece. Journal of Neurology 2004; 251 (suppl III):154
26. Argyriou, P. Polychronopoulos, I. Andriopoulos, S. Papapetropoulos, G. Katsoulas, J. Ellul, S.
    Salakou, E. Chroni: Clinical features of motor neuron disease in southwestern Greece. Journal
    of Neurology 2004; 251 (suppl III):154
27. A. Argyriou, G. Katsoulas, S. Papapetropoulos, P. Talleli, M. Aplada, K. Stavropoulou, V. Sirrou,
    V. Huliara, I. Andriopoulos, E. Gourzoulidou, C. Dimitropoulou and J. Ellul Announcement and
    preliminary results of a randomized controlled study comparing the position of the bevel of
    the needle in the prevention of headache after a diagnostic lumbar puncture. European
    Journal of Neurology 11 (Suppl. 2), P1230
28. A. A. Argyriou, P. Polychronopoulos, S. Papapetropoulos, J. Ellul, G. Katsoulas, S. Salakou and
    E. Chroni. Clinical and epidemiological features of ALS in Southwestern Greece. European
    Journal of Neurology 11 (Suppl. 2), P2568
29. S. Papapetropoulos, A.A. Argyriou, J. Ellul. Factors associated with drug-induced visual
    hallucinations in Parkinson’s disease. Movement Mov Disord (2005) 20 (suppl0);[P172]
30. S. Papapetropoulos, R. Lopez-Alberola, L. Baumbach, A. Russell, M.A. Gonzalez, C. Singer A
    case of maternally transmitted juvenile Huntington’s disease (HD) with a very large
    trinucleotide repeat. Mov Disord (2005) 20 (supp10);[P116]
31. S. Papapetropoulos, A.A. Argyriou, E. Chroni. No correlation between the clinical severity of
    autonomic symptoms (SCOPA-AUT) and electrophysiological test abnormalities in advanced
    Parkinson’s disease. Mov Disord (2005) 20 (supp10);[P173]
32. S. Papapetropoulos, C. Singer. Management of the extrapyramidal syndrome in acquired
    chronic hepatocerebral degeneration (ACHD). Mov Disord (2005) 20 (supp10);[P190]
33. S. Papapetropoulos, J.M. Villar, C. Singer, J. Gonzalez, D.C. Mash. Smoking among patients
    diagnosed with Parkinson’s disease: Is it neuroprotective? Mov Disord (2005) 20
    (supp10);[P395]
34. C. Singer, S. Papapetropoulos, N. Spielholtz. Primary writing tremor successfully treated with
    botulinum toxin injections: Report of two cases. Mov Disord (2005) 20 (supp10);[P564]
35. S. Papapetropoulos, A. Argyriou, P. Polychronopoulos, E. Chroni. Fatal progressive
    neuropathy as a delayed consequence of multiple bites from a non-venomous snake 15th
    Meeting of the European Neurological Society (ENS), Vienna, Austria, 18-22 June 2005. J
    Neurol 2005; 252(suppl 2): 157
36. P. Gourzis, P. Polychronopoulos, A. Argyriou, S. Papapetropoulos, K. Assimakopoulos, S.
    Beratis. Quetiapine treating focal tardive dystonia resulting from administration of atypical
    antipsychotics. 15th Meeting of the European Neurological Society (ENS), Vienna, Austria, 18-
    22 June 2005. J Neurol 2005; 252(suppl 2): 145
37. AA. Argyriou, P. Polychronopoulos, A. Koutras, G. Iconomou, S. Papapetropoulos, G.
    Katsoulas, N. Lepoura, HP. Kalofonos, E. Chroni. Randomized controlled trial of vitamin E
    supplementation for protection against cisplatin and paclitaxel-induced peripheral nerve


                                                                      S. Papapetropoulos MD, PhD
                                                                                                   12
    damage. 9th Congress of the European Federation of Neurological Societies (EFNS), Athens,
    Greece, 17-20 September 2005. Eur J Neurol 2005
38. AA. Argyriou, M. Partheni, P. Polychronopoulos, S. Papapetropoulos, D. Konstantinou, E.
    Chroni. Co-occurrence of meningiomas and demyelination of the central nervous system:
    coincidence or interrelation? Report of two cases. 9th Congress of the European Federation
    of Neurological Societies (EFNS), Athens, Greece, 17-20 September 2005. Eur J Neurol 2005
39. C. Singer, S. Papapetropoulos. Adult-onset primary focal foot dystonia. Park Rel Dis 2005;
    (supp 2) 11:p119
40. D.C. Mash, Y. Qin, Q. Ouyang, S. J. Pablo, S. Papapetropoulos, M. J. Basile. Cocaine abuse
    triggers abnormal expression of alpha-synuclein expression in DA cell bodies and terminals.
    American Academy of Neurology, 57th annual meeting (2005 Miami Beach, FL)
41. C. Singer, S. Papapetropoulos. Post-Immobilization Dystonia in Parkinson s Disease
    American Academy of Neurology, 57th annual meeting (2005 Miami Beach, FL)
42. C. Singer, S. Papapetropoulos. A comparison of jaw-closure and jaw-opening idiopathic
    oromandibular dystonia. 130th Annual Meeting of the American Neurological Association in
    San Diego, California, September 25-27, 2005.
43. S. Papapetropoulos, J. Gonzalez, L. Jean-Gilles, D.C. Mash. Cortical and amygdalar Lewy body
    burden in Parkinson’s disease patients with malignant visual hallucinations. 130th Annual
    Meeting of the American Neurological Association in San Diego, California, September 25-27,
    2005.
44. S. Papapetropoulos, C. Singer. Dysphagia associated with focal oromandibular dystonia.
    130th Annual Meeting of the American Neurological Association in San Diego, California,
    September 25-27, 2005.
45. S. Papapetropoulos, J. Gonzalez, L. Jean-Gilles, D.C. Mash. Extranigral Lewy body density in
    Parkinson's disease patients with visual hallucinations. 35th Society for Neuroscience
    meeting 2006 in Washington DC November
46. D Maraganore, M de Andrade, A Elbaz,M Farrer, J Ioannidis, R Kruger, W Rocca, N Schneider,
    T Lesnick, J Aasly, T Ashizawa, MC Chartier-Harlin, H Checkoway, C Ferrarese, G
    Hadjigeorgiou, N Hattori, H Kawakami, T Lynch, Dublin. G Mellick, S Papapetropoulos, A
    Parsian, A Quattrone, O Riess, EK Tan, C Von Broeckhoven. Collaborative-pooled analysis of
    alpha-synuclein REP1 variability and Parkinson s disease (PD). Neurology (66);5 Supp 2
    IN3.004 (page A330)
47. S Papapetropoulos, JMH ffrench-Mullen, D McCorquandale,. A Buck, P Tarighy, J Pablo, DC
    Mash. Finding molecular targets in Parkinson Disease: Multiregion, high-throughput gene
    array. Neurology (66);5 Supp 2 IN3.010 (page A332)
48. S Papapetropoulos, DC Mash. Increased insular Lewy body density in Parkinson’s disease
    patients with orthostatic hypotension. Neurology (66);5 Supp 2 P04.058 (page A215)
49. B. K. Scanlon, H. L. Katzen, D. A. Nation, R. A. Rodriguez, S. Papapetropoulos, C. Singer, B. V.
    Gallo, B. E. Levin. Neuropsychological Predictors of All-Cause Mortality in Parkinson's
    Disease. INS 2006
50. S.Papapetropoulos, C.Singer. Cranial dystonic syndromes as a presenting symptom of
    Parkinson's disease. 2006 Movement Disorders 21 (S15) P472
51. S.Papapetropoulos; J.M.French-Mullen; D.McCorquondale; Y.Qin; N.C.Adi; J.Pablo; D.C.Mash.
    Multiregion, high - throughput gene expression profiling identifies novel candidate genes for
    Parkinson's disease. 2006 Movement Disorders 21 (S15) P666
52. S.Papapetropoulos; D.C.Mash. Motor fluctuations and dyskinesias in advanced/end stage
    Parkinson's disease: a study from a population of brain donors. 2006 Movement Disorders
    21 (S15) P866
                                                                      S. Papapetropoulos MD, PhD
                                                                                                   13
53. S.Papapetropoulos; M.J.Farrer; J.Stone; D.McCorquodale; L.Calvo; D.C.Mash. Phenotypic
    associations of tau and apoE haplotypes in Parkinson's disease. 2006 Movement Disorders
    21 (S15) P92
54. S.Papapetropoulos; C.Singer. Treatment of primary writing tremor ( PWT ) with botulinum
    toxin type A injections: Report of a case series. 2006 Movement Disorders 21 (S15) P1351
55. S. Papapetropoulos, J. M. Ffrench-mullen, Y. Qin, D. Mccorquodale, A. Buck, J. P. Pablo, D. C.
    Mash;. Multiregion, high-throughput gene expression profiling identifies mitochondrial
    ribosomal protein s6 (mrps6) as a candidate gene for Parkinson’s disease. 36th Society for
    Neuroscience meeting 2006 in Washington DC (October 15th) 173.13/GG9.
56. Nation, D. A., Scanlon, B. K., Katzen, H. L., Rodriguez, R. A., Ledon, J. A., Capano, A.,
    Papapetropoulos, S., Singer, C., Jagid, J. R., & Levin, B. E. (2007, May). Defining features of
    subsyndromal depression in Parkinson’s disease. Poster session presented at the annual
    meeting of the American Academy of Neurology, Boston, MA.
57. Scanlon, B. K., Katzen, H. L., Nation, D. A., Rodriguez, R. A., Papapetropoulos, S., Singer, C.,
    Gallo, B. V., & Levin, B. E. (2007, February). Neuropsychological predictors of all-cause
    mortality in Parkinson’s disease. Poster session presented at the annual meeting of the
    International Neuropsychological Society, Portland, OR
58. S Papapetropoulos, BVGallo, J Jagid, J Zitser, C Sengun, C Singer. Peri- and intra-operative
    electronic monitoring of tremor STN DBS for Parkinson s disease. Poster session presented at
    the annual meeting of the American Academy of Neurology, Boston, MA.
59. R Lopez-Alberola, S Papapetropoulos, D Lorenzo, MA Gonzalez, C Sengun, C Singer,
    Encephalitis lethargica: a reawakening from the past. Poster session presented at the annual
    meeting of the American Academy of Neurology, Boston, MA.
60. S Papapetropoulos, DM Maraganore, N Adi, J ffrench-Mullen, PhD, D McCorquodale, DC Mash.
    Multiregional high-throughput gene expression profiling of Braak regions in Parkinson s
    disease. The Movement Disorder Society's 11th International Congress of Parkinson's
    Disease and Movement Disorders.
61. S Papapetropoulos, N Adi, L Shehadeh, N Bishopric, C Singer, AA Argyriou, E Chroni. Is the
    G2019S LRRK2 mutation common in all southern European populations? The Movement
    Disorder Society's 11th International Congress of Parkinson's Disease and Movement
    Disorders.
62. N Adi, L Shehadeh, DC Mash, C Singer, S Papapetropoulos. Expression of MT1and MT2
    receptors in human postmortem amygdala and substantia nigra of Parkinson s disease and
    controls subjects. The Movement Disorder Society's 11th International Congress of
    Parkinson's Disease and Movement Disorders.
63. S Papapetropoulos, J Jagid, N Ahmad, J Zitser, C Sengun, C Singer, BV Gallo. Low rate of
    complications with unilateral STN-DBS in advanced Parkinson’s disease. The Movement
    Disorder Society's 11th International Congress of Parkinson's Disease and Movement
    Disorders.
64. S Papapetropoulos, N Adi, L Shehadeh, J ffrench−Mullen, N Bishopric and DC Mash. Decreased
    expression of alpha−synuclein in Parkinson s disease: Multiple−level evidence. The
    Movement Disorder Society's 11th International Congress of Parkinson's Disease and
    Movement Disorders.
65. S Papapetropoulos, J Jagid, C Sengun, C Singer, B V Gallo.Objective monitoring of tremor and
    bradykinesia during deep brain stimulation of STN for Parkinson’s disease: A pilot study. The
    Movement Disorder Society's 11th International Congress of Parkinson's Disease and
    Movement Disorders.


                                                                      S. Papapetropoulos MD, PhD
                                                                                                  14
66. S Papapetropoulos, S Baez, J Zitser, C Sengun, C Singer. Retrocollis: classification, clinical
    phenotype, treatment outcomes and risk factors. The Movement Disorder Society's 11th
    International Congress of Parkinson's Disease and Movement Disorders.
67. B K Scanlon, H Katzen, D A Nation, R A Rodriguez, S Papapetropoulos, J A Ledon, A Capano, D
    Wilensky, J Zitser, C Singer, B V Gallo, J A Jagid and B E Levin. Side and Symptom of Disease
    Onset is Related to Lifespan in Parkinson s Disease. The Movement Disorder Society's 11th
    International Congress of Parkinson's Disease and Movement Disorders.
68. D A Nation, H L Katzen, R A Rodriguez, J A Ledon, A Capano, S Papapetropoulos, B V Gallo, J R
    Jagid and B E Levin. Defining Features of Sub-syndromal Depression in Parkinson s Disease.
    The Movement Disorder Society's 11th International Congress of Parkinson's Disease and
    Movement Disorders.
69. S Papapetropoulos, J Friedman, C Blackstone, GI Kleiner, C Sengun, C Singer. A progressive,
    fatal dystonia-parkinsonism syndrome in a patient with primary immunodeficiency receiving
    chronic IVIG therapy. The Movement Disorder Society's 11th International Congress of
    Parkinson's Disease and Movement Disorders.
70. B.E. Levin, H. Katzen, D. Nation, B. Scanlon, D. Wilensky, S. Papapetropoulos, C. Singer. C.
    Sengun, R. Rodriguez. Diagnosing Depression in Parkinson’s Disease: BDI Screening versus
    DSM-IV-TR Criteria. Twenty First Annual Symposium on Etiology, Pathogenesis, and
    Treatment of Parkinson’s Disease and Other Movement Disorders Movement Disorders, Vol.
    22, No. 12, 2007
71. A. Tuchman, C. Sengun, A. Russell, C. Singer, S. Papapetropoulos. Anterocollis: Classification,
    Clinical Phenotype, Treatment Outcomes and Risk Factors. Twenty First Annual Symposium
    on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement
    Disorders Movement Disorders, Vol. 22, No. 12, 2007 1.
72. N.C. Adi, L. Shedah, D. Mash, C. Singer, S. Papapetropoulos. Melatonin receptor expression in
    human postmortem amygdala and substantia nigra of Parkinson s disease and controls
    subjects. Society for Neuroscience, 2007 San Diego, CA.
73. S Papapetropoulos, N. Adi, L. Shehadeh, D.C. Mash. Alpha-synuclein and Septin 4 gene and
    protein expression in Parkinson’s disease human post mortem brains. Society for
    Neuroscience, 2007 San Diego, CA.
74. J.P. Pablo, S.A. Banack, P.A. Cox, T.E. Johnson, S. Papapetropoulos, W.G. Bradley, D.C. Mash.
    Neurotoxic non-protein amino acid BMAA in brain from patients dying with ALS and
    Alzheimer's Disease. Society for Neuroscience, 2007 San Diego, CA.
75. L.A. Shehadeh, N. Tsinoremas, J.M. Vance, N. Adi, S. Papapetropoulos. Melatonin receptor
    expression in human postmortem amygdala and substantia nigra of Parkinson s disease and
    controls subjects. Society for Neuroscience, 2007 San Diego, CA.
76. L.A. Shehadeh, N. Tsinoremas, J.M. Vance, N. Adi, S. Papapetropoulos. The RNA Splicer Gene
    SRRM2 is Differentially Expressed in Parkinson’s Disease. American Society for Human
    Genetics 2007 meeting, San Diego CA.


Invited Talks/Platform Presentations (selected)
1. Specific Clinical Phenotype associated with alpha-synuclein Parkinson’s disease. Institute of
   Neurology, Queen Square, London UK February 3rd 2001
2. Familial Parkinson’s disease in Greece: Clinical Phenotype. The 29th Symposium of the
   European Association of Geriatric Psychiatry, November 2001, Thessaloniki, Greece


                                                                     S. Papapetropoulos MD, PhD
                                                                                               15
3. Psychiatric Symptoms in Parkinson’s disease. University of Miami, Miller School of Medicine,
    Neurology Grand Rounds Lois Pope Life, Center 7th Floor Auditorium Friday, May 7, 2004
4. Unusual Movement Disorders. University of Miami, Miller School of Medicine, Neurology
    Grand Rounds Lois Pope Life, Center 7th Floor Auditorium Friday, September 9, 2005
5. BMAA in brain tissues. BMAA: Cyanobacteria, Ecosystems, and Human Health Spring Creek
    Ranch, Jackson Hole, Wyoming, USA October 11–14, 2005
6. BMAA in human tissues. University of Miami, Rosenstiel School of Marine and Atmospheric
    Sciences. Monday December 5, 2005
7. Tauopathies and Movement Disorders: A Clinical Review. NEUROLOGICAL UPDATE 2006
    January 25-28, 2006 The Alexander Hotel Miami Beach, FL
8. BMAA in Relation to Neurodegeneration. Environmental Neurotoxins and Human Health The
    Kampong, Coconut Grove, Florida Thursday, January 26, 2006
9. Gene expression profiling in Parkinson’s disease. Genetic Epidemiology of Parkinson’s
    disease 2nd Annual Meeting, 10-12 September 2006, Santorini, Greece
10. Clinical aspects of tauopathies. BMAA: Testing the Hypothesis Spring Creek Ranch, Jackson
    Hole, Wyoming, USA October 9–13, 2006
11. Gene expression profiling in Parkinson’s disease. University of Miami, Miller School of
    Medicine, Neurology Grand Rounds Lois Pope Life, Center 7th Floor Auditorium Friday,
    November 17, 2006
12. Clinical phenotypes of genetic forms of Parkinson’s disease. Dr. John T. Macdonald
    Foundation Center for Medical Genetics, GENETICS CONFERENCE, December 12, 2006
13. Gene Expression Profiling in PD: Identification of novel molecular targets using a
    multiregional approach. Dr. John T. Macdonald Foundation Center for Medical Genetics,
    GENETICS CONFERENCE, December 12, 2006
14. Gene Expression Profiling in PD, Mayo Clinic Rochester MN, December 16th 2006
15. ALS: What causes it? NTBG Florida Physicians’ Course. The Kampong, Coconut Grove, Florida
    February 15-17, 2007
16. Hallucinations and psychosis in PD: Phenotypic and treatment considerations Neurology
    Grand Rounds, Michigan State University 1/18/ 2007
17. Multiregional high-throughput gene expression profiling in Parkinson’s disease: the process
    of novel pathway and target identification. Neuroscience Grand Rounds, Michigan State
    University 1/18/ 2007
18. A Video Presentation of Movement Disorder Cases. NEUROLOGICAL UPDATE 2007 January
    24-27, 2007 The Alexander Hotel Miami Beach, FL
19. Animal model studies of BMAA toxicity. 4th International Symposium “ BMAA: Its occurrence
    and potential threat to human health”. Dalarö, Stockholm, Sweden August 20-23, 2007
    Karolinska Institute, Sweden
20. Alpha-synuclein and Septin 4 gene and protein expression in Parkinson’s disease human post
    mortem brains. November 3rd 2007, Society for Neuroscience Meeting, San Diego, CA.


Teaching
Teaching Specialization: Neurology, Neuroscience and Movement Disorders with over 5 years
of experience.
8/2002-9/2003: Teaching faculty and Course Director in Behavioral Neurology. Technological
Educational Institute of Patras, Greece, School Of Health And Welfare Professions, Dept. Of
Speech And Language Therapy. (http://www.teipat.gr/pages/logo/logoth_eng.htm)
                                                                  S. Papapetropoulos MD, PhD
                                                                                                 16
Graduate/Undergraduate Teaching:
Directly supervised undergraduate/graduate students during my appointment. Currently
supervising research post-doctoral fellows and clinical Movement Disorders fellows. Actively
involved in teaching and training of basic scientists and clinicians in the Department of
Neurology. Current Teaching activities include:
  1. Medical student Case-based Neurology Training conducted by the Center for Research in
     Medical Education (CRME) of the University of Miami, Miller School of Medicine.
  2. Neurology Resident training through monthly lunch seminars in Movement Disorders.
  3. Movement Disorders Clinical Fellow training and supervision.


Book Chapters
S. Papapetropoulos, C. Singer. A case of seizures, orofacial dyskinesias and peripheral
neuropathy. In: Movement Disorders 100 Instructive cases. Editor: R. Reich, Publisher: Informa
Healthcare, Abingdon UK (2006)


Other
1. Associate Editor of the Year Book of Neurology and Neurosurgery. Mosby Publishers
2. Organizer of the 2nd Annual Meeting on the Genetic Epidemiology of Parkinson’s disease
   (http://www.geopdmeeting2006.gr)
3. Peer reviewer for: Annals of Neurology, Neurology, Movement Disorders, European Journal
   of Neurology, Journal of Neurology, Expert Review of Neurotherapeutics, Drugs & Aging,
   Neuroscience Letters, Biomarkers in Medicine, Marine Drugs and others.
4. Permanent resident of the USA


Research Support:
C. Research Projects Ongoing
1. “The basis of psychotic symptoms in Parkinson’s disease”- Principal Investigator: Dr. Spiridon
Papapetropoulos. Source/Agency: National Institute of Mental Health (NIMH).Type: R03 (PA-03-
108). Period of support: 1/4/2007-31/3/2009.
2. “Cyanobacterial toxin (BMAA) in postmortem brain tissue and hair samples of ALS/PD/AD
patients”. Principal Investigator: Dr. Spiridon Papapetropoulos Source/Agency: Muscular
Dystrophy Association (MDA) Research Department. Period of support: 2/1/2006-1/31/2008.
3. “Cyanobacterial toxin (BMAA) in brain and hair tissue of AD patients”. Principal Investigator:
Dr. Spiridon Papapetropoulos. Source/Agency: Alzheimer’s Association- New Investigator
Grant. Period of support: 7/1/2006-1/31/2008.
4. “Peripheral blood gene expression profiling: discovery of valid biomarkers” – Principal
Investigator: Spiridon Papapetropoulos. Source/Agency: University of Miami Scientific Awards
Committee Research Grant. Period of Support: 9/1/2007-8/31/2008
5. “Weight Loss in Parkinson’s disease”- Principal Investigator: Spiridon Papapetropoulos.
Source/Agency: Parkinson’s Foundation/Parkinson Study Group. Period of Support: 12/1/2007-
11/31/2008


                                                                    S. Papapetropoulos MD, PhD
                                                                                                17


D. Completed Projects
1. "Post-mortem neurochemical investigations of visual hallucinations in Parkinson’s disease
brain donors". Principal Investigator: Dr. Spiridon Papapetropoulos. Source/Agency: Stanley J.
Glaser Foundation Biomedical Research Support Grant. Period of support: February 1, 2006
through January 31, 2007




                                                                   S. Papapetropoulos MD, PhD

								
To top